Nirogacestat

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Ovarian Granulosa-Stromal Tumor

Drug Information

Target Indication

Ovarian Granulosa-Stromal Tumor

Clinical Trial

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals

EMA8/14/2025

Ogsiveo

Ogsiveo as monotherapy is indicated for the treatment of adult patients with progressing desmoid tumours who require systemic treatment.

Orphan

Drug Science

Mechanism of action & safety profile

Developer

SWTX

SpringWorks Therapeutics, Inc.

Related Pipeline

Desmoid Tumor

Pancreatic Cancer

Plexiform Neurofibroma

Covid19

Anus Neoplasms

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts